Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Mycobacterium tuberculosis and the response of its host
-
2. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
3. Immune response and rational development of vaccines and biomarkers
- Prof. Dr. Stefan H. E. Kaufmann
-
4. Molecular mechanisms of drug resistance in M. tuberculosis
- Dr. Daniela Cirillo
- The epidemiology of tuberculosis
-
5. The basic epidemiology of tuberculosis (TB)
- Dr. David Dowdy
-
6. Global epidemiology of TB
- Dr. Philippe Glaziou
-
7. Social determinants of tuberculosis
- Dr. Knut Lönnroth
- The control of tuberculosis
-
8. Treatment of tuberculosis
- Dr. Jean-Pierre Zellweger
-
9. The End TB Strategy towards TB elimination 1
- Dr. Mario Raviglione
-
10. The End TB Strategy towards TB elimination 2
- Dr. Mario Raviglione
-
11. Financing TB care and control
- Dr. Christopher Fitzpatrick
- Dr. Andrea Pantoja
-
12. Tuberculosis and COVID-19
- Prof. Giovanni Battista Migliori
-
13. Multidrug resistant tuberculosis (MDR-TB): an update
- Dr. Simon Tiberi
-
14. Impact of HIV on tuberculosis in the developing world and how to manage it
- Prof. Anthony D. Harries
-
16. TB in children
- Prof. Ben J. Marais
-
17. Community engagement in tuberculosis care
- Ms. Lana Syed
-
18. India: the epicentre of global TB control
- Dr. Madhukar Pai
-
19. Community engagement in TB care
- Dr. Haileyesus Getahun
- Research and development for new approaches in the control of tuberculosis
-
20. Development of new regimens for tuberculosis
- Dr. Zhenkun Ma
-
22. Pharmacometrics in tuberculosis
- Prof. Charles A. Peloquin
-
23. Extrapulmonary tuberculosis
- Dr. Scott Heysell
-
24. The role of surgery in tuberculosis management
- Dr. Richard Zaleskis
- Archived Lectures *These may not cover the latest advances in the field
-
25. The development of current treatments for tuberculosis
- Dr. Andrew Nunn
-
26. The pathogenesis of tuberculosis
- Dr. William R. Bishai
-
27. Basics of tuberculosis epidemiology
- Prof. Frank Cobelens
-
29. The international approach to the control of tuberculosis
- Dr. Mario Raviglione
-
30. Public-private mix for TB care and control
- Dr. Mukund Uplekar
Printable Handouts
Navigable Slide Index
- Introduction
- Drugs FDA approved for tuberculosis (TB)
- Drugs not FDA approved for TB (1)
- Drugs not FDA approved for TB (2)
- PA-824
- OPC-67683 (Delamanid)
- TMC207 (Bedaquiline)
- Isoniazid (INH)
- Rifampin (RIF)
- Rifabutin (RBN)
- Comparison of rifamycins
- Unique features of rifamycins
- Pyrazinamide (PZA)
- Ethambutol (EMB)
- Streptomycin (SM)
- Amikacin, kanamycin, capreomycin (AK, KM, CM)
- Levofloxacin (Levo)
- Moxifloxacin (Moxi)
- Ethionamide (ETA)
- p-Aminosalicylic acid (PAS)
- Cycloserine (CS)
- How do antibiotics work? (1)
- How do antibiotics work? (2)
- How do antibiotics work? (3)
- Pharmacokinetics (PK)
- Pharmacodynamics (PD)
- Response & toxicity curves (1)
- Usual PK-PD response parameters
- PD: response parameters
- Isoniazid curves
- Ethionamide curves
- "Concentration dependent" antimicrobials
- Sterilizing activity of rifampin
- Rifampin kinetics study
- Response & toxicity curves (2)
- Rifampin 600 mg in humans
- Rifampin 1200 mg in humans
- Rifampin 600 mg versus 1200 mg
- Rifampin 1200 mg
- Response & toxicity curves (3)
- Pharmacokinetics study of rifabutin & isoniazid
- Lesser 23A study
- Lesser rifabutin AUC with ARR versus cure
- Recap (TB drugs)
- Recap (rifamycin)
- Recap (PK-PD and TB)
- Role for therapeutic drug monitoring (TDM)
- TDM and acquired rifamycin resistance (1)
- TDM and acquired rifamycin resistance (2)
- Further reading
- Contact info
Topics Covered
- FDA approved drugs for tuberculosis
- Non-FDA approved drugs for tuberculosis
- How do antibiotics work?
- Pharmacokinetics and pharmacodynamics
- Pharmacodynamics of isoniazid and ethionamide
- "Concentration dependent" antimicrobials
- Concentration dependent activity of rifampin
- Concentration dependent activity of isoniazid and rifabutin
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Peloquin, C.A. (2014, December 2). Pharmacometrics in tuberculosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 30, 2024, from https://doi.org/10.69645/BHGZ1133.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Charles A. Peloquin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to Pharmacometrics
in Tuberculosis.
My name is Chuck Peloquin.
I'm a professor at the University
of Florida College of Pharmacy
and the University of Florida
Emerging Pathogens Institute.
Today, we'll be talking about
the drugs that are used to treat
tuberculosis and some other key
features to using them properly.
0:23
Slide two shows the drugs
that are FDA, or Food and Drug
Administration, approved for
treatment of tuberculosis
in the United States.
Very similar lists of drugs
are available in countries
around the world.
Some countries have more limited
formularies, and the second line
drugs, and we'll
discuss what that means,
are available through
programs offered
by the World Health
Organization, or WHO.
Aminosalicylate, also known
as aminosalicylic acid or PAS,
is the oldest of the TB drugs,
discovered in the early 1940s
in Sweden, and that was followed
very shortly by the discovery
of streptomycin, the first
of the aminoglycosides.
The third TB drug to be
introduced was isoniazid, or INH,
and with the introduction
of isoniazid,
true combination therapy that
was actually quite effective
now was possible, and that
was in the early 1950s.
Continuing down the list from the
top, capreomycin is a polypeptide.
It's also an injectable
drug like streptomycin,
so there is no oral dosage form.
We'll talk a little bit more
about all of these drugs
in subsequent slides.
Cycloserine also is
considered a second line
drug, as is ethionamide.
Ethambutol, pyrazinamide,
rifampin, and rifapentine all
can be considered first line drugs.